MAPT and Alzheimer disease: Unfortunately, to date, nearly all of the interventions targeting Aβ and tau protein hyperphosphorylation in AD have failed in phase III clinical trials [193–195], including immunotherapies, drugs reducing Aβ production or enhancing Aβ clearance, as well as drugs inhibiting tau phosphorylation or aggregation in these years [196–198].